Phase I/II study of myeloablative allogeneic stem cell transplantation for aggressive Hematologic Malignancies using clofarabine and busulfan x 4 (Clo/BU4) regimen.

Trial Profile

Phase I/II study of myeloablative allogeneic stem cell transplantation for aggressive Hematologic Malignancies using clofarabine and busulfan x 4 (Clo/BU4) regimen.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2015

At a glance

  • Drugs Clofarabine (Primary) ; Busulfan
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Mar 2010 Planned end date changed from 1 Sep 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 20 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top